MDM2 and neoplasm: The PKPD model of HDM201 also demonstrated that the anti-tumor activity of HDM201 was not scheduled dependent, but was related to cumulative dose [81], suggesting the feasibility of clinical intermittent administration to reduce the common hematological toxicity of MDM2 inhibitors.